Want to see NGEN full AI Analyst Report?
NervGen Pharma (NGEN) Financial Statements
NervGen Pharma Financial Overview
NervGen Pharma's market cap is currently $147.43M. The company's EPS TTM is $-0.85; its P/E ratio is -2.25; NervGen Pharma is estimated to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.10. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -83.74K | $ -145.01K | $ -114.10K | $ -42.95K |
| Operating Income | $ -25.08M | $ -24.92M | $ -17.78M | $ -22.82M | $ -12.91M |
| EBITDA | $ -5.65M | $ -23.91M | $ -22.24M | $ -19.92M | $ -12.78M |
| Net Income | $ -44.12M | $ -23.99M | $ -22.38M | $ -20.54M | $ -12.82M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 22.07M | $ 17.35M | $ 11.66M | $ 22.25M | $ 17.06M |
| Total Assets | $ 23.21M | $ 19.47M | $ 13.24M | $ 23.67M | $ 18.03M |
| Total Debt | $ 8.37K | $ 105.53K | $ 197.21K | $ 280.96K | $ 0.00 |
| Net Debt | $ -22.06M | $ -17.15M | $ -11.46M | $ -21.97M | $ -17.06M |
| Total Liabilities | $ 19.73M | $ 16.90M | $ 15.25M | $ 10.32M | $ 1.09M |
| Stockholders' Equity | $ 3.48M | $ 2.57M | $ -2.01M | $ 13.34M | $ 16.95M |
| Cash Flow | |||||
| Free Cash Flow | $ -19.50M | $ -16.83M | $ -11.30M | $ -17.65M | $ -8.33M |
| Operating Cash Flow | $ -19.50M | $ -16.83M | $ -11.30M | $ -17.63M | $ -8.33M |
| Investing Cash Flow | $ 100.93K | $ 58.83K | $ -138.87K | $ -20.92K | $ -45.43K |
| Financing Cash Flow | $ 23.76M | $ 22.68M | $ 766.35K | $ 22.44M | $ 19.76M |
Currency in CAD